Currently the main treatment strategies for MHD patients with active HCV replication, but how to increase the sustained virological response and decrease the side effects is the key problem. IFNα-free treatments with two or three direct-acting antivirals without ribavirin in MHD patients are waiting for future investigations.

Key words: Hemodialysis; Hepatitis C virus; Epidemiology; Risk factors; Prophylaxis; Treatment

Core tip: The new hepatitis C virus (HCV) infections during maintenance hemodialysis (MHD) in recent years are mainly caused by the lack of stringent universal precautions. Strict implementation of universal precautions for HCV transmission has led to markedly decreased HCV infections in many hemodialysis units, but the anti-HCV negative HCV infection and occult HCV infection in MHD patients still should be noted. How to increase the sustained virological response and decrease the side effects is the key problem for the currently recommended interferon alpha-based antiviral therapy in MHD patients. Interferon alpha-free treatments with two or three direct-acting antivirals without ribavirin in MHD patients are waiting for future investigations.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

INTRODUCTION

Hepatitis C virus (HCV) infection is a major public health problem worldwide which can lead to chronic hepatitis
C, liver cirrhosis and hepatocellular carcinoma (HCC)\cite{1,2}. Prevalence of HCV infection is markedly higher in patients on maintenance hemodialysis (MHD)\cite{3,4}. Chronic HCV infection detrimentally affects the life quality, decreases life expectancy, leads to renal transplant rejection, and increases the mortality of MHD patients suffering from chronic kidney failure\cite{4,5,6}. Moreover, HCV infection has been shown to increase the prevalence of renal insufficiency, defined by serum creatinine $\geq 1.5$ mg/dL; the mechanisms may include the direct HCV-related renal injury and HCV-related cirrhosis with subsequent renal impairment\cite{7}, and this will be harmful for patients who receive renal transplantation. The rates of HCV infection in MHD patients vary markedly among different countries and hospitals. Multiple factors are associated with the high risk of HCV transmission in MHD patients\cite{2,3,4,8-10}. Standard interferon alpha (ST-IFN$\alpha$) and pegylated IFN$\alpha$ (PEG-IFN$\alpha$) are currently the main treatment strategies for HCV infection in MHD patients, and the key problems are how to increase the sustained virological response (SVR), control the side effects and minimize the dropout rates\cite{1,2,3,8-10}. This review summarizes the advancement in understanding the prevalence, risk factors, monitoring strategy, and more importantly, prophylaxis and treatment of HCV infection in MHD patients.

### EPIDEMIOLOGY

HCV infection in hemodialysis patients varies by patients’ behavioral and cultural differences, geographic location, socioeconomic aspects, community exposure factors, number of patients per hemodialyzer and rigorous use of the strictest biosafety standards\cite{1,2}, with the reported prevalence ranging from 1.9% to 90% (Table 1)\cite{1-5}. Generally, new cases of HCV infection related to hemodialysis are more frequent in regions that have a higher prevalence of serum anti-HCV, and HCV genotypes in hemodialysis patients are usually in accordance with those found in non-hemodialysis patients; but some HCV genotypes that are rare in the general population may be more prevalent in hemodialysis patients because of the nosocomial person-to-person transmission in the hemodialysis unit\cite{1}. For instance, a higher prevalence of HCV genotype 2b has been found in hemodialysis populations in southern Brazil, a genotype rarely occurring in Brazil, where the 1a, 1b, or 3a are more common\cite{11}.

### RISK FACTORS

Currently, it is still unclear how MHD patients become HCV-infected. Nevertheless, both intradialysis (number of blood transfusions, duration and mode of dialysis, prevalence of HCV in the hemodialysis unit, breakdown of standard infection control practices) and extra dialysis (high risk of lifestyle behaviour) variables have been identified.

First, many of these patients had severe uremic anemia needing blood transfusion, which is the most important route of HCV transmission\cite{12}. Thus, it was highly possible that some of the hemodialysis patients got HCV infection through this way, especially in regions with poor socioeconomic conditions, where the qualified medical staff and equipments available to treat MHD patients were very limited. In the past two decades, the sensitivity and specificity of laboratory tests for detection of HCV have improved greatly, leading to the more stringent screening of blood donors and the marked decline of new HCV infections\cite{13,14,15}. On the other hand, the availability of erythropoietin has reduced the need of blood transfusion in MHD patients significantly in many countries\cite{16,17}.

Second, new HCV infections can occur in patients who lack the risk factors of blood transfusion, intravenous drug use, high-risk sexual activity, or exposure to known HCV-positive persons. It is believed that these patients were infected by HCV during the course of hemodialysis\cite{18}. Phylogenetic analysis of HCV isolates implies that many HCV infections during hemodialysis

### Table 1. Prevalence of anti-hepatitis C virus seropositivity in hemodialysis patients

| Country/region | Prevalence | Investigators and year of publication |
|----------------|------------|--------------------------------------|
| Slovenia       | 1.9%       | Buturović-Porikvar et al\cite{21}, 2001 |
| Netherlands    | 3.4%       | Schneeberger et al\cite{19}, 1999   |
| Puerto Rico    | 3.5%       | López-Navedo et al\cite{19}, 1999   |
| United Kingdom | 4.0%       | Wreght\cite{19}, 1999               |
| Germany        | 6.1%       | Hinrichsen et al\cite{19}, 2002     |
| Mexico         | 6.7%       | Mendez-Sanchez et al\cite{19}, 2004 |
| Belgium        | 6.8%       | Jadoul et al\cite{19}, 2004         |
| United States  | 7%-23.3%   | Kalantar-Zadeh et al\cite{19}, 2007 |
|                |            | Kalantar-Zadeh et al\cite{19}, 2005 |
|                |            | Sivapalasingam et al\cite{19}, 2002 |
|                |            | Kelley et al\cite{19}, 2002         |
|                |            | Saab et al\cite{19}, 2001            |
| Brazil         | 6%-90%     | da Silva et al\cite{19}, 2013       |
|                |            | Mello Lde et al\cite{19}, 2007      |
|                |            | Lopes et al\cite{19}, 2006          |
|                |            | Albuquerque et al\cite{19}, 2005    |
|                |            | Carneiro et al\cite{19}, 2001       |
| China Mainland | 7.01%-37.34% | Ren et al\cite{19}, 2011         |
|                |            | Qi et al\cite{19}, 2003              |
| Greece         | 10%-29%    | Garinis et al\cite{19}, 1999       |
|                |            | Rigopoulos et al\cite{19}, 2005     |
|                |            | Sypsa et al\cite{19}, 2005          |
| Sweden         | 11.0%      | Almothe et al\cite{19}, 2002        |
| Iran           | 13.2%      | Alavian et al\cite{19}, 2003        |
| France         | 16.3%      | Salama et al\cite{19}, 2000        |
| Tunisia        | 19%-41.7%  | Bougargour et al\cite{19}, 2005     |
|                |            | Ayed et al\cite{19}, 2003           |
| Libya          | 20.5%      | Daw et al\cite{19}, 2002            |
| Italy          | 22.5%-32.1% | Petrosillo et al\cite{19}, 2003    |
|                |            | Lombardi et al\cite{19}, 1999      |
| Sudan          | 23.7%      | El-Amin et al\cite{19}, 2007        |
| Vietnam        | 26.6%      | Dunford et al\cite{19}, 2012        |
| Bosnia and Herzegovina | 59.0% | Ahmetagi et al\cite{19}, 2006 |
| Peru           | 59.3%      | Sanchez et al\cite{19}, 2000       |
| Kuwait         | 71.0%      | Wreght\cite{19}, 1999              |
| Moldavia       | 75.0%      | Covic et al\cite{19}, 1999          |
| Senegal        | 80.0%      | Dind et al\cite{19}, 2000           |
are surely the result of nosocomial patient-to-patient transmission\[^{[45,47-50]}\]. The infection risk usually increases with the prevalence of HCV, and the number and length of hemodialysis exposure in corresponding hemodialysis units\[^{[45,51,60]}\]. Recently, da Silva et al\[^{[4]}\] reported that HCV-infected patients had been on hemodialysis for 91.9 mo, more prolonged than HCV-negative patients (\(P = 0.001\)). Another investigation showed that the prevalence of HCV infection at admission in a New York City hemodialysis unit was 18%, far higher than the 1.6% in the United States population overall. During 2001-2008, nine patients treated in this unit were found to have seroconversion from anti-HCV negative to positive. Of them the sources for four HCV infections were identified phylogenetically and epidemiologically as four other patients in the unit. The epidemiologic and site investigations showed that the hemodialysis unit had inadequate HCV infection surveillance and patient follow-up, inadequate cleaning and disinfection practices, failing to wear or change gloves or perform hand hygiene between contacted patients, lack of a separate clean area for medication storage and preparation, and short turnover periods between patient treatments\[^{[47]}\]. Accordingly, it is suspected that the way for HCV transmission in these patients may be direct percutaneous exposure to infectious blood because of inadequate infection control\[^{[1]}\]. On the contrary, the use of dedicated hemodialyzer specially prepared for each patient and the strict implementation of hygienic precautions against HCV transmission could markedly decrease the incidence of nosocomial HCV infection in hemodialysis patients\[^{[46]}\].

**MONITORING**

Monitoring serum anti-HCV by enzyme-linked immunosorbent assay or enzyme immunoassay every three to six months is essential to identify HCV seroconversion\[^{[46,47]}\]. Sometimes the recombinant immunoblot assay for anti-HCV should be added to confirm the positivity of anti-HCV\[^{[47]}\]. Of note is that the anti-HCV tests may fail to detect HCV infection in 1.66%\[^{[48]}\] to 7.2%\[^{[49]}\] of MHD patients, because the immunocompromised status of these patients prevents them from having detectable anti-HCV antibodies\[^{[1]}\]. So it is necessary to detect HCV core antigen by chemiluminescent assay or HCV RNA by polymerase chain reaction (PCR) in anti-HCV negative patients who are at high risk of HCV transmission\[^{[46,48]}\]. If HCV RNA is positive, it is necessary to quantitate and genotype the HCV RNA further to provide important information for phylogenetic analysis of HCV isolates and selection of treatment strategy in MHD patients\[^{[49,50]}\]. In addition, serum alanine aminotransferase (ALT) and other liver-associated biochemical tests, alpha fetoprotein and ultrasonic scan of the liver should also be conducted regularly.

Occult HCV infection, defined as detectable HCV RNA in the liver or peripheral blood mononuclear cells (PBMCs) in the absence of both serum HCV RNA and anti-HCV\[^{[51]}\], is a serious fact that might be ignored in hemodialysis patients. Barril et al\[^{[5]}\] reported that occult HCV infection, determined by the presence of genomic HCV RNA in PBMCs, was found in 45% of the 109 MHD patients, and 53% of these patients had ongoing HCV replication indicated by the presence of antigenomic HCV RNA. Patients with occult HCV infection had spent a significantly longer time on hemodialysis and had significantly higher mean ALT levels during the 6 mo before study entry. Accordingly, for patients with long time of hemodialysis and a relatively higher serum ALT level, the PBMCs or liver biopsy samples should be collected to detect HCV RNA to rule out occult HCV infection\[^{[51,52]}\].

**PROPHYLAXIS**

There is no active vaccine to prevent MHD patients from HCV infection. It has been adopted by many medical centers to assign HCV-infected patients to dedicated hemodialysis machines in a dedicated room in order to separate HCV positive patients from the negative patients, and this has been considered to be able to decrease the risk of HCV transmission\[^{[53]}\]. In those hemodialysis units with high HCV prevalence but without fulltime medical staff on HCV-infection control, this strategy may help decrease the risk of HCV transmission among patients\[^{[44]}\]; but for hemodialysis units with strict universal precautions against HCV transmission, some specialists consider that the dedicated hemodialysis machine in a dedicated room for HCV-infected patients is somewhat unjustified and unnecessary\[^{[46,54]}\].

Universal precautions, especially stringent adherence of all necessary biosafety measures during hemodialysis, are considered to be the keystones to minimize HCV transmission related to hemodialysis and have maximized ideal prophylactic effects\[^{[46,47,53]}\]. These measures include: (1) applying a disposable hemodialyzer to avoid sharing of a hemodialyzer; (2) systematic decontamination of the equipment and circuits after each patient’s treatment; (3) avoiding sharing of medications, such as multiuse vials of heparin among patients; (4) avoiding sharing of instruments such as tourniquets; (5) preparing any medications in a separate area; (6) disinfecting hemodialysis station surfaces timely; (7) cleaning hands and changing gloves before contacting different patients; (8) periodic testing of all patients for anti-HCV and HCV RNA; and (9) systematic training of health workers in hemodialysis units.

**TREATMENT**

HCV infection has a significant adverse effect on the health of persons with chronic kidney disease, leads to a higher mortality in MHD patients than non-infected MHD patients, and reduces the survival rates of patients who undergo kidney transplantation, as do their grafts. Moreover, HCV infection renders the patients at high risk of developing diabetes mellitus, membranous glomerulonephritis as well as fibrosing cholestatic hepatitis after
Table 2  Current recommendations for antiviral treatment of hepatitis C virus infection in maintenance hemodialysis patients with kidney failure[1,8-10,54,56,57]

| Drug          | Dosage                  | Notes                                                                 |
|---------------|-------------------------|-----------------------------------------------------------------------|
| ST-IFNα-2a    | 3 million units, three times a week | Usually 48 wk for HCV genotypes 1 and 4, and 24 wk for HCV genotypes 2 and 3, or receiving response-guided treatment |
| ST-IFNα-2b    | 3 million units, three times a week | A more reduced dose, a longer interval between two injections, or temporary cessation of IFNα should be considered in patients with severe side effects such as dangerous bone marrow suppression |
| PEG-IFNα-2a   | 135 μg, once a week     | Ribavirin is applied in combination with interferon, and should be prohibited if severe anemia or other adverse effects occurs |
| PEG-IFNα-2b   | 1 μg/kg, once a week    | Ribavirin is applied in combination with interferon, and should be prohibited if severe anemia or other adverse effects occurs |
| Ribavirin     | 200 mg, once a day, every other day, or thrice weekly after hemodialysis | Ribavirin is applied in combination with interferon, and should be prohibited if severe anemia or other adverse effects occurs |

HCV: Hepatitis C virus; ST-IFNα: Standard interferon alpha; PEG-IFNα: Pegylated interferon alpha.

kidney transplantation[1]. Accordingly, patients with MHD who are infected with HCV should be treated if conditions permit, no matter whether they will receive kidney transplantation or not. On the other hand, occult HCV infection is usually persistent and can not be eradicated spontaneously. Though it seems to be less aggressive than chronic hepatitis C, occult HCV infection may also lead to liver cirrhosis and even HCC[52,53]. Accordingly, if occult HCV infection could be confirmed in MHD patients, the antiviral therapy should be given too[49]. Recommendations for the treatment of HCV infection in MHD patients with kidney failure are summarized in Table 2.

ST-IFNα and PEG-IFNα monotherapies are currently the main treatment strategies for MHD patients with active HCV RNA replication. For adult patients, ST-IFNα-2a or ST-IFNα-2b should be given at a reduced dose of 3 million units three times a week, and PEG-IFNα-2a or PEG-IFNα-2b should be given at a reduced dose of 135 μg and 1 μg/kg once a week, respectively[10]. If the patients still cannot endure the side effects even in the use of erythropoietin, granulocyte-macrophage colony stimulating factor, interleukin-11 or other symptomatic and supporting treatments, a more reduced dose of IFNα should be given, and/or the intervals between two injections should be prolonged, or the IFNα should be stopped temporarily. Generally, the recommended treatment duration of IFNα is based on the HCV genotypes, *i.e.*, 48 wk for HCV genotypes 1 and 4, and 24 wk for HCV genotypes 2 and 3[10], but the response-guided treatment strategy should also be emphasized, *e.g.*, shorter treatment duration for patients achieving rapid virological response (defined as seronegativity of HCV RNA at week 4 of treatment) than those with early virological response (EVR, defined as seronegativity of HCV RNA at week 12 of treatment), and early termination in those without an EVR[8]. Moreover, a shorter treatment duration of IFNα might be considered in patients with interleukin-28B (IL-28B) genotype rs12979860 CC or rs8099917 TT, but a longer treatment duration should be given in those with IL-28B genotype rs12979860 CT/TT or rs8099917 TG/GG[56].

Though PEG-IFNα can be used and may be associated with improved SVR rates in MHD patients[53], a group of experts in both kidney and liver disease recommended ST-IFNα in preference to PEG-IFNα for the treatment of MHD patients with HCV infection[1]. The rationale for this recommendation is that ST-IFNα has appeared as effective as PEG-IFNα in MHD persons because its exposition is reduced in these patients, its adverse effects may be lower, and management of adverse effects is relatively easier than PEG-IFNα[8].

Because ribavirin has the high risk of inducing or aggravating hemolytic anemia in uremic patients and can not be removed by hemodialysis, it should be prohibited or used at a markedly reduced daily dose with careful monitoring of anemia and other adverse effects in MHD patients[10,14,20]. If RBV is to be applied, it should be given at an individualized dosing of 200 mg once a day, or 200 mg every other day, or 200 mg thrice weekly after hemodialysis, and substantial hematopoietic support is essential[53].

In a meta-analysis made by Gordon et al[8] in 2009, which included 428 patients from 20 prospective studies from 1966 to February 2009, IFNα treatment for at least six months against chronic HCV infection in MHD patients was shown to result in a high overall SVR of 45%. Both univariate and multivariate regression analyses demonstrated that the higher SVR was related to the following factors: (1) three million units or higher dosage of IFNα, three times weekly; (2) completion of treatment for at least six months; (3) lower baseline HCV RNA; (4) female gender; and (5) early virological negativity[8]. In a later meta-analysis by Alavian et al[8] published in 2010, 491 MHD patients from 21 studies of ST-IFNα and ST-IFNα monotherapy in random effects model were 39.1% and 39.3%, respectively. Pooled dropout rates were 22.6% and 29.7%, respectively. Only age less than 40 years was significantly associated with SVR. HCV RNA level, HCV genotype, ALT pattern, female gender, duration of infection, liver fibrosis stage, and treatment duration were not significantly associated with SVR[8]. These conclusions are conflicting with that of Gordon et al[8]. Accordingly, the factors associated with the SVR are worthy of further investigations.

Tolerance to initial IFNα monotherapy was lower in MHD than in non uremic patients with chronic HCV infection. The most frequent side effects requiring interruption of treatment were severe flu-like symptoms, bone marrow suppression, neurological and gastrointestinal
discomfort. However, about 40% of MHD patients with HCV infection have been successfully treated with IFNα monotherapy. Further studies are warranted to define whether longer duration of IFNα monotherapy will have a better SVR on IFNα for chronic hepatitis C in MHD population[58].

Telaprevir and boceprevir are HCV protease inhibitors (PIs) developed in recent years. No significant impact of renal dysfunction on telaprevir or boceprevir exposure was found in patients with end-stage renal disease[58], suggested that both drugs might be used to treat HCV infection in this setting[57]. A recent study that included 36 treatment-naïve HCV genotype 1 infected MHD patients showed that telaprevir-containing triple therapy had superior efficacy than PEG-IFNα/RBV dual therapy, but was accompanied with anemia more frequently and severely[57]. Generally speaking, in consideration of added severe side effects and drug-drug interactions, triple or quadruple combinations based on IFNα/RBV therapy with one or two PIs are believed not very suitable for MHD patients with HCV infection. On the other hand, several IFNα-free clinical studies combining two or three new direct antiviral agents without RBV are now under investigation in HCV-infected patients without renal dysfunction[57]. This will bring new hopes to increase SVR with decreased side effects not only for HCV-infected patients without MHD, but also for patients with MHD.

CONCLUSION

MHD patients without initial HCV infection may be infected by HCV through blood transfusion or negligence of universal precautions during hemodialysis. The application of erythropoietin has decreased the necessity of blood transfusion for uremic anemia greatly, and the improved detection tests of anti-HCV, HCV core antigen and HCV RNA have minimized the risk of HCV transmission through blood transfusion. Accordingly, the new HCV infections during MHD in recent years are mainly caused by the lack of standard universal precautions. Construction of detailed surveillance systems and implementation of stringent universal precautions for HCV transmission have led to a markedly decreased prevalence of HCV infection in many hemodialysis units[58], and the effectiveness of different preventive strategies for HCV infection in hemodialysis units should be further investigated and clarified. The occult HCV infection in MHD patients should be paid more attention, and detection of HCV RNA by PCR from PBMCs or liver biopsy is necessary for MHD patients with unexplainable elevated serum ALT or liver cirrhosis. Currently, ST-IFNα and PEG-IFNα monotherapies at a reduced dose are the main treatment strategies for MHD patients with active HCV replication, and the SVRs are up to 40% or so. The emphases of future study for the treatment of HCV infection in MHD patients include how to increase the SVR, how the genetic factors such as polymorphisms of IL-28B gene will affect the SVR, how to optimize the treatment duration, how to conquer the side effects of IFNα, and whether IFNα-free treatments with two or three DAAs without RBV are effective and practical for HCV eradication in MHD patients[2].

ACKNOWLEDGMENTS

We wish to thank Professor Cheng Wei Chen and Jin Lin Hou for their helpful discussions and taking the time to read through our manuscript.

REFERENCES

1 Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]

2 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI: 10.1038/nm.3248]

3 Alavian SM. A shield against a monster: Hepatitis C in hemodialysis patients. World J Gastroenterol 2009; 15: 641-646 [PMID: 19222088 DOI: 10.3748/wjg.15.641]

4 da Silva NM, Germano FN, Mendosa-Sassi RA, Seuánez HN, Soares MA, de Martinez AM. Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil. Virol J 2013; 10: 167 [PMID: 23714239 DOI: 10.1186/1743-422X-10-167]

5 Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-1593 [PMID: 17429053 DOI: 10.1681/ASN.2006070736]

6 Li Cavoli G, Zagarrigo C, Schillaci O, S ervillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotulo U. Hepatitis C virus core antigen test in monitoring of dialysis patients. H epat Res Treat 2012; 2012: 832021 [PMID: 23304475 DOI: 10.1155/2012/832021]

7 Dunford L, Carr MJ, Dean J, Waters A, Nguyen LT, Ta Thi TH, Thi LA, Do HD, Thi TT, Nguyen HT, Diem Do TT, Luu QP, Connell J, Coughlan S, Nguyen HT, Hall WW, Nguyen Thi LA. Hepatitis C virus in Vietnam: high prevalence of infection in dialysis and multi-transfused patients involving diverse and novel virus variants. PLoS One 2012; 7: e41266 [PMID: 22916104 DOI: 10.1371/journal.pone.0041266]

8 Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010; 4: 181-194 [PMID: 20622035]

9 Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis—an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 2009; 4: 1449-1458 [PMID: 19643927 DOI: 10.2215/CJN.01850309]

10 Fabrizi F, Dulai G, Dixit V, Bunnappadist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-1081 [PMID: 14653826 DOI: 10.1046/j.1365-2036.2003.01780.x]

11 Bianco A, Bova F, Nobile CG, Pileggi C, Pavia M. Healthcare workers and prevention of hepatitis C virus transmission: exploring knowledge, attitudes and evidence-based practices in hemodialysis units in Italy. BMC Infect Dis 2013; 13: 76 [PMID: 23391009 DOI: 10.1186/1471-2334-13-76]

12 Buturović-Ponikvar J. Renal replacement therapy in Slovenia: annual report 2001. Nephrol Dial Transplant 2003; 18
HCV infection in hemodialysis

Yu YC et al.

Suppl 5: v53-v55 [PMID: 12817072]

Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, Sanna R, van Der Heijden TG, van Den Hoven H, van Hamersveld HW, Quint W, van Doorn LJ. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000; 182: 1291-1299 [PMID: 11032452]

López-Navedo PJ, Lebrón-Rivera G, González-Trápaga J, Weber-Acevedo J, Lefevre-Ramos E, Flores-de Hostos E, Jaume-Anselmi F, Ramírez-Rivera J. Prevalence of hepatitis C virus infection at three hemodialysis units in the western region of Puerto Rico. Bol Asoc Med P R 1999; 91: 100-102 [PMID: 10842442]

Wreghtt IG. Blood-borne virus infections in dialysis units -a review. Rev Med Virol 1999; 9: 101-109 [PMID: 10386337]

Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433 [PMID: 12171969]

Méndez-Sánchez N, Motela-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-4322 [PMID: 15365034 DOI: 10.1128/JCM.42.9.4321-4322.2004]

Jadoul M, Poignet JL, Gedeas C, Locatelli F, Medin C, Krajevska M, Barril G, Schuermann E, Sonkodi S, Goubau P. The changing epidemiology of hepatitis C virus infections in patients with chronic renal failure. Transplantation 2000; 69: 319-324 [PMID: 11325683]

Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46: 290-300 [PMID: 16112048]

Sivapalasingam S, Malak SF, Sullivan JF, Lorch J, Sepkowitz KA. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect Control Hosp Epidemiol 2002; 23: 319-324 [PMID: 12083235]

Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, Nolte FS. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: 904-909 [PMID: 15031348 DOI: 10.1093/ndt/gfh012]

Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 44-51 [PMID: 10745231]

Bouzagrou N, Fodha I, Othman SB, Achour A, Grattard V. Detection and prevention of hepatitis C virus infection in dialysis patients and renal transplant recipients. A long-term follow up (1989-January 1997). J Intern Med 2002; 251: 119-128 [PMID: 11905887]

Alavian SM, Einollahi B, Hajarizadeh B, Bahktiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian hemodialysis patients. Nephrolog (Carlston) 2003; 8: 256-260 [PMID: 15012714]

Aked Y, Gorgi Y, Ben Abdallah T, Aoudai H, Jendoubi-Ayed S, Sfar I, Makni H. Hepatitis C virus infection in hemodialysis patients from Tunisia: national survey by serologic and molecular methods. Transplant Proc 2003; 35: 2573-2575 [PMID: 14612022]

Daw MA, Elkebar MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J 2005; 27: 502-508 [PMID: 16254976]

El-Amin HH, Osman EM, Meikki MO, Abdelraheem MB, Issa AI, Yousif ME, Assab AM, Al-haj HS, Ammar HK. Hepatitis C virus infection in hemodialysis patients in Sudan: two centers’ report. Saudi J Kidney Dis Transplant 2007; 18: 101-106 [PMID: 17257901]

Ahmetagic S, Muninmohdiz K, Cickusi E, Stojic V, Petrovic J, Tihic N. Hepatitis C infection in risk groups. Bosn J Basic Med Sci 2006; 6: 13-17 [PMID: 17177641]

Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, Constantine NT, Hyams KC, Hinirostra S, Figueroa-Barrios R, Guthie JC. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and
genotype distribution. Am J Trop Med Hyg 2000; 63: 242-248
[PMID: 11421731]
43 Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Miltiatic I, Covic M. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14: 40-45 [PMID: 10052474]
44 Diouf M, Diouf B, Niang A, Ka EH, Pouye A, Seck A, Ra- phenon G, Moreira-Diop T. [Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar]. Dakar Med 2000; 45: 1-4 [PMID: 14666779]
45 Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magni- tude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008; 28: 628-640 [PMID: 18285684 DOI: 10.1159/000117573]
46 Moini M, Ziayaeyan M, Aghaee S, Sagheb MM, Taghavi SA, Moeini M, Jamalidoust M, Hamidpour L. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon 2013; 13: e9147 [PMID: 24052048 DOI: 10.5812/hepatmon.9147]
47 Centers for Disease Control and Prevention (CDC). Hepa- titis C virus transmission at an outpatient hemodialysis unit.-New York, 2001-2008. MMWR Morb Mortal Wkly Rep 2009; 58: 189-194 [PMID: 19265779]
48 Izopet J, Sandres-Sauñé K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-76 [PMID: 16032714]
49 Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouqi Z, Ben Redjeb S, Izopet J. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol 2006; 78: 185-191 [PMID: 16372289]
50 Delaroque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, Couroucé AM, Astagneau P, Buissen C, Desenclos JC. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialy- sis machine? Infect Control Hosp Epidemiol 2002; 23: 328-334 [PMID: 12083237]
51 Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valde- casas J, Garcia-Fernández N, González-Farri E, Akazar JM, Sánchez C, Diez-Baylón JC, Martínez P, Bartolomé J, Carreño V. Occult hepatitis C virus infection among hemodialysis pa- tients. J Am Soc Nephrol 2008; 19: 2288-2292 [PMID: 18684893 DOI: 10.1681/ASN.2008030293]
52 Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspec- tives in occult hepatitis C virus infection. World J Gastroen- terol 2012; 18: 2887-2894 [PMID: 22736911 DOI: 10.3748/wjg.v18.i23.2887]
53 Hussein MM, Mooij JM. Methods used to reduce the prevale- nce of hepatitis C in a dialysis unit. Saudi J Kidney Dis Transpl 2010; 21: 909-913 [PMID: 20814130]
54 Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, di- agnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; (109): S1-599 [PMID: 18382440 DOI: 10.1038/ki.2008.81]
55 Keyhani H, Bokharaei-Salim F, Monavari SH, Eghaei M, Nassari Toosi M, Fakhim S, Sadigh ZA, Alavian SM. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 2013; 13: e11290 [PMID: 24082889 DOI: 10.5812/hepatmon.11290]
56 Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat 2013; 20: 761-769 [PMID: 24168255 DOI: 10.1111/jvh.12097]
57 European Association for Study of Liver. EASL Clinical Prac- tice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j. jhep.2013.11.003]
58 Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O’Mara E, Kassem A, Gupta S, Hughes EA. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012; 51: 619-628 [PMID: 22799589 DOI: 10.2165/11633440-000000000-00000]

P- Reviewers: Kuhns MC, Lankarani KB S- Editor: Song XX L- Editor: Wang TQ E- Editor: Liu SQ
